Literature DB >> 29444925

Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada.

D Thiwanka Wijeratne1, Katherine Lajkosz1, Susan B Brogly1, M Diane Lougheed1, Li Jiang1, Ahmad Housin1, David Barber1, Ana Johnson1, Katharine M Doliszny1, Stephen L Archer2.   

Abstract

BACKGROUND: The World Health Organization recognizes 5 groups of pulmonary hypertension (PH), categorized by pathogenesis or comorbidity: 1-pulmonary arterial hypertension 2-left-heart disease, 3-lung disease and hypoxia 4-chronic thromboembolic disease, and 5-miscellaneous. The epidemiology of PH, apart from group 1, is largely unknown. METHODS AND
RESULTS: We describe incidence, prevalence, comorbidities, mortality and prescribing patterns for groups 1 to 4 PH from 1993 to 2012. Case definitions are based on hospitalizations and emergency department visits, using the Institute for Clinical Evaluative Sciences data, which comprises linked databases of universal coverage health service records for Ontario residents. This cohort included 50 529 patients with PH. The annual incidence of adult PH increased from 2003 to 2012 from 24.1 to 28.7 cases/100 000 population and the annual prevalence from 1993 to 2012 from 99.8 to 127.3 cases/100 000 population, respectively. The most common form of adult PH was group 2, alone (34.2%) or combined with group 3 PH (29.3%). A diagnosis of PH increased the 1-year standardized mortality ratio 7.2-fold. Mortality in adults with PH was 13.0%, 36.4%, and 62.4%, at 30 days, 1 year, and 5 years, respectively. Mortality was highest in groups 2 and 3 and lowest in group 1. PH was present in only 3.6% of people with left heart disease, 0.7% with lung disease, and 1.4% with thromboembolic disease, suggesting that PH is a relatively rare complication of these common diseases. Children (age<16 years) accounted for 3.6% of the cohort. In children group 1 PH was most common (65.2%), and 5-year mortality was lower (21.4%) than in adults. Group 1-specific PH therapies were increasingly prescribed over time and paradoxically were often used in patients who seemed to have group 2, PH based on diagnostic codes indicating left heart disease.
CONCLUSIONS: The incidence and prevalence of adult PH are increasing. Groups 2 and 3 are the most common and lethal forms of PH. This study identifies an emerging epidemic of PH that likely has substantial adverse health and economic implications.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  comorbidity; heart diseases; hypertension, pulmonary; hypoxia; incidence; lung diseases; prevalence

Mesh:

Substances:

Year:  2018        PMID: 29444925      PMCID: PMC5819352          DOI: 10.1161/CIRCOUTCOMES.117.003973

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  26 in total

1.  Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension.

Authors:  Garvan C Kane; Hilal Maradit-Kremers; Josh P Slusser; Chris G Scott; Robert P Frantz; Michael D McGoon
Journal:  Chest       Date:  2010-11-11       Impact factor: 9.410

2.  Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension.

Authors:  Micah R Fisher; Paul R Forfia; Elzbieta Chamera; Traci Housten-Harris; Hunter C Champion; Reda E Girgis; Mary C Corretti; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2009-01-22       Impact factor: 21.405

3.  A USA-based registry for pulmonary arterial hypertension: 1982-2006.

Authors:  T Thenappan; S J Shah; S Rich; M Gomberg-Maitland
Journal:  Eur Respir J       Date:  2007-09-05       Impact factor: 16.671

4.  Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis.

Authors:  Janet E Pope; Peter Lee; Murray Baron; James Dunne; Douglas Smith; Peter S Docherty; Arthur Bookman; Maysan Abu-Hakima
Journal:  J Rheumatol       Date:  2005-07       Impact factor: 4.666

5.  Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era.

Authors:  Rui Zhang; Li-Zhi Dai; Wei-Ping Xie; Zai-Xin Yu; Bing-Xiang Wu; Lei Pan; Ping Yuan; Xin Jiang; Jing He; Marc Humbert; Zhi-Cheng Jing
Journal:  Chest       Date:  2011-02-17       Impact factor: 9.410

6.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

7.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

Authors:  David B Badesch; Gary E Raskob; C Greg Elliott; Abby M Krichman; Harrison W Farber; Adaani E Frost; Robyn J Barst; Raymond L Benza; Theodore G Liou; Michelle Turner; Scott Giles; Kathy Feldkircher; Dave P Miller; Michael D McGoon
Journal:  Chest       Date:  2009-10-16       Impact factor: 9.410

8.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

9.  Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society.

Authors:  Steven H Abman; Georg Hansmann; Stephen L Archer; D Dunbar Ivy; Ian Adatia; Wendy K Chung; Brian D Hanna; Erika B Rosenzweig; J Usha Raj; David Cornfield; Kurt R Stenmark; Robin Steinhorn; Bernard Thébaud; Jeffrey R Fineman; Titus Kuehne; Jeffrey A Feinstein; Mark K Friedberg; Michael Earing; Robyn J Barst; Roberta L Keller; John P Kinsella; Mary Mullen; Robin Deterding; Thomas Kulik; George Mallory; Tilman Humpl; David L Wessel
Journal:  Circulation       Date:  2015-11-03       Impact factor: 29.690

10.  Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland.

Authors:  Yi Ling; Martin K Johnson; David G Kiely; Robin Condliffe; Charlie A Elliot; J Simon R Gibbs; Luke S Howard; Joanna Pepke-Zaba; Karen K K Sheares; Paul A Corris; Andrew J Fisher; James L Lordan; Sean Gaine; J Gerry Coghlan; S John Wort; Michael A Gatzoulis; Andrew J Peacock
Journal:  Am J Respir Crit Care Med       Date:  2012-07-12       Impact factor: 21.405

View more
  58 in total

1.  Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.

Authors:  Lauren Rose; Kurt W Prins; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Jeffrey R Misialek; Thenappan Thenappan
Journal:  J Heart Lung Transplant       Date:  2018-09-14       Impact factor: 10.247

2.  Accuracy of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data: A Systematic Review.

Authors:  Kari R Gillmeyer; Ming-Ming Lee; Alissa P Link; Elizabeth S Klings; Seppo T Rinne; Renda Soylemez Wiener
Journal:  Chest       Date:  2018-11-22       Impact factor: 9.410

Review 3.  Management of arrhythmias in pulmonary hypertension.

Authors:  S Ashwin Reddy; Sarah L Nethercott; Bharat V Khialani; Andrew A Grace; Claire A Martin
Journal:  J Interv Card Electrophysiol       Date:  2021-04-05       Impact factor: 1.900

4.  Radiographic pulmonary vessel volume, lung function and airways disease in the Framingham Heart Study.

Authors:  Andrew J Synn; Wenyuan Li; Raúl San José Estépar; Chunyi Zhang; George R Washko; George T O'Connor; Tetsuro Araki; Hiroto Hatabu; Alexander A Bankier; Murray A Mittleman; Mary B Rice
Journal:  Eur Respir J       Date:  2019-09-12       Impact factor: 16.671

Review 5.  Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

Authors:  Monika Spaczyńska; Susana F Rocha; Eduardo Oliver
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01

6.  Novel Mutations and Decreased Expression of the Epigenetic Regulator TET2 in Pulmonary Arterial Hypertension.

Authors:  François Potus; Michael W Pauciulo; Elina K Cook; Na Zhu; Alexander Hsieh; Carrie L Welch; Yufeng Shen; Lian Tian; Patricia Lima; Jeffrey Mewburn; Christine L D'Arsigny; Katie A Lutz; Anna W Coleman; Rachel Damico; Brooke Snetsinger; Ashley Y Martin; Paul M Hassoun; William C Nichols; Wendy K Chung; Michael J Rauh; Stephen L Archer
Journal:  Circulation       Date:  2020-03-20       Impact factor: 29.690

7.  Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015.

Authors:  Kari R Gillmeyer; Seppo T Rinne; Mark E Glickman; Kyung Min Lee; Qing Shao; Shirley X Qian; Elizabeth S Klings; Bradley A Maron; Joseph T Hanlon; Donald R Miller; Renda Soylemez Wiener
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-05-12

8.  Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension: Temporal Trends, Predictors, and Outcomes.

Authors:  Vidhu Anand; Saraschandra Vallabhajosyula; Wisit Cheungpasitporn; Robert P Frantz; Hector R Cajigas; Jacob J Strand; Hilary M DuBrock
Journal:  Chest       Date:  2020-08-12       Impact factor: 9.410

9.  AGE-RAGE Stress in the Pathophysiology of Pulmonary Hypertension and its Treatment.

Authors:  Kailash Prasad
Journal:  Int J Angiol       Date:  2019-04-19

10.  Exercise Pulmonary Hypertension Predicts Clinical Outcomes in Patients With Dyspnea on Effort.

Authors:  Jennifer E Ho; Emily K Zern; Emily S Lau; Luke Wooster; Cole S Bailey; Thomas Cunningham; Aaron S Eisman; Kathryn M Hardin; Robyn Farrell; John A Sbarbaro; Mark W Schoenike; Nicholas E Houstis; Aaron L Baggish; Ravi V Shah; Matthew Nayor; Rajeev Malhotra; Gregory D Lewis
Journal:  J Am Coll Cardiol       Date:  2020-01-07       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.